Bausch + Lomb BLCO Contingent consideration fair value adjustments

Contingent consideration fair value adjustments at other companies

Bristol-Myers SquibbBMY

$15M—

AbbVieABBV

——

Revenue$1.2B+9.4%

Operating income$33.0M+140%

Net income-$71.0M+66.5%

EPS (diluted)-$0.20+66.7%

Cash & equivalents$279.0M+29.8%

Total debt$5.0B+4.3%

Total equity$6.4B+0.3%

Total assets$13.8B+2.6%

Operating cash flow$32.0M+228%

CapEx$100.0M-9.1%

Free cash flow-$68.0M+49.6%

Market cap$5.3B+10.2%

Operating margin4.4%+2.9pp

Net margin-4.2%-1.3pp

FCF margin-3.4%0.0pp

Return on equity-3.4%-0.9pp

Debt / equity0.8×0.0×

Current ratio1.5×0.0×

Reported directly by Bausch + Lomb in its filing.

Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1.

The official record: Bausch + Lomb’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Bausch + Lomb's contingent consideration fair value adjustments?: Bausch + Lomb (BLCO) reported contingent consideration fair value adjustments of $2M in Q1 2026.
How has Bausch + Lomb's contingent consideration fair value adjustments changed year-over-year?: Bausch + Lomb's contingent consideration fair value adjustments increased by 122.2% year-over-year, from -$9M to $2M.